Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GeoVax Labs, Inc. - Common Stock (NQ:GOVX)

0.9700 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about GeoVax Labs, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
GeoVax Highlights Dual Protective Potential of GEO-CM04S1 Following Presentation at the AAI Annual Meeting 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
GeoVax Highlights Dual Protective Potential of GEO-CM04S1 Following Presentation at the AAI Annual Meeting 2025
GEO-CM04S1 Demonstrates Robust COVID-19 and Mpox Immunogenicity in Immunocompromised Patients and Healthy Adults 
Via TheNewswire.com
Exposures COVID-19
GeoVax Expands Gedeptin(R) Patent Portfolio
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property
GeoVax Expands Gedeptin(R) Patent Portfolio
Allowed Patent Claims Cover the Synergistic Combination of Gedeptin® Therapy with Radiation As a Targeted Approach for Solid Tumors 
Via TheNewswire.com
Topics Intellectual Property
Exposures Intellectual Property
GeoVax Applauds White House Executive Order Supporting U.S. Pharmaceutical Manufacturing; Highlights Progress in Domestic MVA Vaccine Production
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Economy Government
Exposures COVID-19 Political Supply Chain
GeoVax Presents Gedeptin(R) Clinical Data at the American Association for Cancer Research Annual Meeting
Advancing Gene-Directed Prodrug Therapy: Data Presented at AACR Supports Gedeptin’s Potential in Solid Tumors 
Via TheNewswire.com
GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC Operations
Recognized Biologics Executive to Oversee Critical Expansion of U.S.-Based Development Capabilities 
Via TheNewswire.com
GeoVax Applauds White House Executive Order Supporting U.S. Pharmaceutical Manufacturing; Highlights Progress in Domestic MVA Vaccine Production
Company’s Advanced Manufacturing Proposal Supports National Biosecurity Goals and Executive Action on Domestic Pharmaceutical Supply Chains 
Via TheNewswire.com
Topics Economy Government
Exposures COVID-19 Political Supply Chain
GeoVax Reports First Quarter 2025 Financial Results and Provides Business Update
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
GeoVax Reports First Quarter 2025 Financial Results and Provides Business Update
COVID-19 vaccine program progressing with additional data evaluating GEO-CM04S1 as booster to mRNA vaccines in healthy adults expected in second quarter of 2025 
Via TheNewswire.com
Exposures COVID-19
GeoVax Presents Gedeptin(R) Clinical Data at the American Association for Cancer Research Annual Meeting
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Responds to Detection of Clade I Mpox in North Carolina Wastewater
GEO-MVA Advancing as the Leading U.S.-Developed Mpox Vaccine Candidate 
Via TheNewswire.com
Topics Supply Chain
Exposures Supply Chain
GeoVax Responds to Detection of Clade I Mpox in North Carolina Wastewater
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Supply Chain
Exposures Supply Chain
GeoVax Highlights Strong Clinical Results Following Presentation of Multi-Antigen COVID-19 Vaccine at the 25th Annual World Vaccine Congress
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
GeoVax Highlights Strong Clinical Results Following Presentation of Multi-Antigen COVID-19 Vaccine at the 25th Annual World Vaccine Congress
GEO-CM04S1 Demonstrates Durable T Cell and Antibody Responses in Healthy and Immunocompromised Populations 
Via TheNewswire.com
Exposures COVID-19
GeoVax to Report First Quarter 2025 Financial Results and Provide Corporate Update on May 1, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
GeoVax to Report First Quarter 2025 Financial Results and Provide Corporate Update on May 1, 2025
GeoVax to Host Conference Call at 4:30 PM ET 
Via TheNewswire.com
Exposures COVID-19
GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC Operations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Highlights New Study Demonstrating the Strength of Multi-Antigen COVID-19 Vaccine Candidates
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
GeoVax Highlights New Study Demonstrating the Strength of Multi-Antigen COVID-19 Vaccine Candidates
Peer-Reviewed Data Reinforces GeoVax’s Multi-Antigen Strategy With GEO-CM02 and Supports Advancement of GEO-CM04S1 Clinical Programs 
Via TheNewswire.com
Exposures COVID-19
GeoVax Provides Update on BARDA Project NextGen and Outlines 2025 Business Momentum
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
GeoVax to Present at the Emerging Growth Conference on April 16, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
GeoVax to Present Clinical Data at Upcoming April Industry Events
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
GeoVax Receives USPTO Notice of Allowance for Marburg Hemorrhagic Fever Vaccine Patent
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property Product Safety
GeoVax Receives USPTO Notice of Allowance for Marburg Hemorrhagic Fever Vaccine Patent
Continues to Strengthen Its Pandemic Preparedness and Biodefense Vaccine Portfolio 
Via TheNewswire.com
Topics Intellectual Property
Exposures COVID-19 Intellectual Property Product Safety
GeoVax Reports 2024 Year-End Financial Results and Provides Business Update
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Reports 2024 Year-End Financial Results and Provides Business Update
GEO-CM04S1 BARDA/Project NextGen Phase 2b trial preparations ongoing with manufacturing of clinical trial materials underway and clinical sites confirmed 
Via TheNewswire.com
GeoVax Labs Announces $4.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Regulatory Compliance
Exposures Legal Regulatory
GeoVax Labs Announces $4.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
ATLANTA, GA - March 24, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases,... 
Via TheNewswire.com
Topics Regulatory Compliance
Exposures Legal Regulatory
GeoVax to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.